GENFIT Share Price Other OTC
Equities
GNFTF
FR0004163111
Biotechnology & Medical Research
Sales 2024 * | 89.63M 96.35M 7.71B | Sales 2025 * | 48.78M 52.44M 4.2B | Capitalization | 163M 175M 14.02B |
---|---|---|---|---|---|
Net income 2024 * | 15M 16.12M 1.29B | Net income 2025 * | -21M -22.57M -1.81B | EV / Sales 2024 * | 1.51 x |
Net cash position 2024 * | 27.6M 29.67M 2.37B | Net cash position 2025 * | 44.9M 48.27M 3.86B | EV / Sales 2025 * | 2.42 x |
P/E ratio 2024 * |
6.98
x | P/E ratio 2025 * |
25.2
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.71% |
Latest transcript on GENFIT
Managers | Title | Age | Since |
---|---|---|---|
Pascal Prigent
CEO | Chief Executive Officer | 56 | 30/04/18 |
Founder | 68 | 31/08/99 | |
Thomas Baetz
DFI | Director of Finance/CFO | 50 | 21/04/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 67 | 03/03/21 | |
Founder | 68 | 31/08/99 | |
Founder | 52 | 14/09/99 |
1st Jan change | Capi. | |
---|---|---|
+21.74% | 46.81B | |
-0.97% | 41.37B | |
+47.07% | 41.29B | |
-3.52% | 28.87B | |
+11.12% | 26.06B | |
-19.37% | 19.13B | |
+31.18% | 12.39B | |
-0.04% | 12.08B | |
+0.39% | 11.96B |